Thursday, Jul 02, 2020 | Last Update : 03:47 PM IST

100th Day Of Lockdown

Maharashtra180298931548053 Tamil Nadu94049529261264 Delhi89802599922803 Gujarat33318240381869 Uttar Pradesh2405616629718 West Bengal1917012528683 Rajasthan1831214574421 Telangana173578082267 Karnataka165148065253 Andhra Pradesh152526988193 Haryana1494110499240 Madhya Pradesh1386110655581 Bihar10204781173 Assam8956583212 Jammu and Kashmir76954856105 Odisha7316535333 Punjab56683989149 Kerala4594243626 Uttarakhand2791190937 Chhatisgarh2339193713 Jharkhand2339160512 Tripura140110931 Manipur12605790 Goa11984783 Himachal Pradesh9796179 Puducherry73930112 Nagaland5351820 Chandigarh4463676 Arunachal Pradesh182601 Mizoram1601230 Sikkim88490 Meghalaya50421
  Business   Companies  26 May 2020  India's Glenmark to test potential covid19 drug combination

India's Glenmark to test potential covid19 drug combination

REUTERS
Published : May 26, 2020, 12:28 pm IST
Updated : May 26, 2020, 12:33 pm IST

Glenmark is already conducting clinical trials in India of just favipiravir as a potential treatment for COVID-19

 India's Glenmark to test potential covid19 drug combination. ( Photo- Glenmark Pharma)
  India's Glenmark to test potential covid19 drug combination. ( Photo- Glenmark Pharma)

BENGALURU: Glenmark Pharmaceuticals Ltd said on Tuesday it will begin a new clinical trial in India to test a combination of two anti-viral drugs, favipiravir and umifenovir, as a potential COVID-19 treatment.

The study will look to enroll 158 hospitalized patients suffering from moderate COVID-19 infections in India, the company said.

 

Drugmakers across the world have been rushing to develop a treatment or vaccine for the fast-spreading coronavirus, which has infected 5.5 million people globally, killing more than 345,000, according to a Reuters tally.

In India, now among the 10 most affected nations, the death toll from COVID-19 reached 4,167 on Tuesday.

Favipiravir is made under the brand name Avigan by Japan’s Fujifilm Holdings Corp and was approved for use as an anti-flu drug there in 2014, while umifenovir is licensed as a treatment of some types of flu infections in Russia and China.

Glenmark is already conducting clinical trials in India of just favipiravir as a potential treatment for COVID-19, for which it expects results by July or August. Favipiravir is also undergoing trials in other countries.

Tags: glenmark pharmaceuticals, clinical trial, india, anti-viral drugs, favipiravir, umifenovir, covid-19 treatment
Location: India, Karnataka, Bengaluru